Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy

Virology. 2011 Jan 20;409(2):328-37. doi: 10.1016/j.virol.2010.10.021. Epub 2010 Nov 10.

Abstract

In 2001, Jackson et al. reported that murine IL-4 expression by a recombinant ectromelia virus caused enhanced morbidity and lethality in resistant C57BL/6 mice as well as overcame protective immune memory responses. To achieve a more thorough understanding of this phenomenon and to assess a variety of countermeasures, we constructed a series of ECTV recombinants encoding murine IL-4 under the control of promoters of different strengths and temporal regulation. We showed that the ECTV-IL-4 recombinant expressing the highest level of IL-4 was uniformly lethal for C57BL/6 mice even when previously immunized. The lethality of the ECTV-IL-4 recombinants resulted from virus-expressed IL-4 signaling through the IL-4 receptor but was not due to IL-4 toxicity. A number of treatment approaches were evaluated against the most virulent IL-4 encoding virus. The most efficacious therapy was a combination of two antiviral drugs (CMX001(®) and ST-246(®)) that have different mechanisms of action.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Benzamides / therapeutic use
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • Ectromelia virus / genetics
  • Ectromelia virus / immunology*
  • Ectromelia virus / pathogenicity*
  • Ectromelia, Infectious / drug therapy
  • Ectromelia, Infectious / virology
  • Female
  • Gene Expression Regulation
  • Interleukin-4 / biosynthesis*
  • Interleukin-4 / genetics
  • Interleukin-4 / immunology*
  • Isoindoles / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Organophosphonates / therapeutic use
  • Promoter Regions, Genetic
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Benzamides
  • Isoindoles
  • Organophosphonates
  • Recombinant Proteins
  • Interleukin-4
  • brincidofovir
  • Cytosine
  • tecovirimat